chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Initial report was retrieved from the scientific literature on 06 September 2012. The following information is verbatim from the abstract: "Meningococci have historically caused extensive illness among members. Three successive meningococcal vaccine types were used from 1971 through 2010; overall disease incidence dropped by >90% during this period. During 2006-2010, disease incidence of 0.38 (cases per 100,000 person-years) among members was not significantly different from the incidence of 0.26 among the age-matched general population. Of the 26 cases, 5 were fatal, 15 were vaccine failures (e.g., illness in a person who had been vaccinated), and 9 were caused by Neisseria meningitidis serogroup Y. Incidences among 17- to 19-year old trainees and among others were significantly higher than among comparison populations (p<0.05). No apparent change in epidemiology of meningococcal disease was observed after replacement of quadrivalent polysaccharide vaccine with conjugate vaccine in 2007. The data demonstrate that vaccination with meningococcal vaccine is effective." According to the report, the cases were confirmed by culture, PCR or both. The information included in this case concerns a 20-24 year-old male patient who had received MENOMUNE A/C/Y/W-135 (lot number, route, site and date of administration not reported) and seven months after vaccination developed meningococcal meningitis, year reported as 2006 (Q4). Neisseria meningitidis serogroup was determined to be serogroup C. Treatments were not reported. No further information was available at the time of report. Death was reported as "No", however the patient's outcome was not reported. The reporter for this case is the same as for cases 2012-08240, -08241, -08242, -08244, -08245, -08246, -08247, -08248, -08249, -08250, -08251, -08252, -08253, -08254, -08255, and -08256. Documents held by sender: None.
Our kid had cough and cold symptom, so we tested him, and he was negative. My wife had the same symptoms she tested negative as well. All this happened days before me. I had a slight cough and a headache. I tested positive for COVID-19 on October 22, and I called my primary care doctor. The doctor gave me PAXLOVID after checking the COVID-19 results. I was better within a few days.
Allergic reaction to shots, red , swollen skin and itching. BENADRYL. Temperature 97.7 on 08/09/2006, temperature 96.2 on 08/12/2006.
5/17/06 1430 VACCINE ADM L/DELTOID IM .5ML 5/19/06 0945 FIRST REPORT. LEFT UPPER ARM RED, WARM, SWOLLEN AREA APPROX 4 1/2". ACHING, TENDER TO TOUCH.  IBUPROFEN PO AND ICE TO SITE. 5/20/06 SEEN @ CLINIC. DX CELLULITIS, RX MEDROL PACK, KEFLEX & KENOLOG CREAM. 10LB WEIGHT RESTRICTION. F/U 48 HRS WITH CLINIC. 5/22/06 F/U CLINIC VISIT, RETURN TO FULL DUTY. CONTINUE MEDS AS PRESCRIBED.
Subsequent to receiving vax, this pt experienced a "shingles reaction." She sought medical treatment and was prescribed acyclovir for 7 days. The lesion were reported as "crusted."  Follow up states patient experienced red, warm, swollen left hand and arm with blisters covering the entire area. Patient had a fever of 101F. No further information is available.
Severe Nausea- early morning. At night upon going to bed , severe stomach, abdominal and back pain. Lasted all night long - could not get into a position to lessen pain. Got out of bed in the morning and sat for a while. Went back to bed a couple hours later, propped myself up on bed, pain subsided after a couple hours. Spoke with the nurse at my doctors-she advised most likely effects from the second COVID shot
Severe fever (temp not stated), chills on1/19 and then started with vomiting on 1/20    Has since recovered.
I have second effect with the vaccine; This case was reported by a consumer via call center representative and described the occurrence of adverse drug reaction in a 64-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced adverse drug reaction. On an unknown date, the outcome of the adverse drug reaction was unknown.   It was unknown if the reporter considered the adverse drug reaction to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient had second effect with the vaccine.
Post vax, the pt developed hives on his face, trunk, and extremities. A doctor or ER visit was required and he was treated with Benadryl and Zyrtec liquid on 4/27/00.
The day after receiving her 2nd dose of the COVID-19 (Pfizer) vaccination, patient came back to the pharmacy reporting a rash all over her body. I referred her to the closest urgent care where she received a steroid shot.
This spontaneous report as received from a secretary referred to a patient of unknown age. The patient was vaccinated with dose 1 and 2 of GARDASIL, two years ago, in 2009 and with dose 3 on 12-JUL-2012. No other co-suspects were reported. No concomitant medications were reported. No adverse effect was reported. No treatment information was reported. Additional information has been requested.
28 hours post vaccine I noticed a rash on my chest and upper back.   The rash was not raised and did not itch, but there was a mild tingling sensation to it.  40 hours post vaccine the rash  included my neck, stomach, upper back, and chest.   The rash was not raised and did not itch, but there was a mild tingling sensation to it.  The rash seemed to be the most intense between 40 to 44 hours post vaccine.  Following 44 hours post vaccine the rash began to gradually lighten and the tingling disappeared.  At 52 hours post vaccine the rash was barely noticeable in color with no tingling.
EYE SWELLING; EYE REDNESS; CHEEKS SWELLING; CHEEKS REDNESS; This spontaneous report received from a patient concerned a 58 year old female. The patient's height, and weight were not reported. The patient's pre-existing medical conditions included the patient was not pregnant at the time of reporting. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 207A21A expiry: UNKNOWN) dose was not reported, administered on 10-APR-2021 for prophylactic vaccination. No concomitant medications were reported. On 13-APR-2021, the subject experienced eye swelling. On 13-APR-2021, the subject experienced eye redness. On 13-APR-2021, the subject experienced cheeks swelling. On 13-APR-2021, the subject experienced cheeks redness. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient had not recovered from eye swelling, eye redness, cheeks swelling, and cheeks redness. This report was non-serious.
Information has been received from a physician concerning a 16 weeks old female patient who in December 2009 was vaccinated with a dose of ROTATEQ (route and lot # unknown) at 16 weeks of age. The physician stated the she was a "micro preemie" and she was not released from the hospital until 16 weeks. No adverse effects reported. The patient sought medical attention at the physician's office. This is one of several reports from the same source. Additional information has been requested. This is an amended report. The ONUM of multiple=2 was deleted. The report's reportability changed from do not send to periodic.
I had shortness of breath, weight gain and soon after I was diagnosed with heart failure. I had a cough, I couldn't sleep laying down from fluid retention.
second dose early; slight headache; This spontaneous case was reported by a consumer and describes the occurrence of OFF LABEL USE (second dose early) and HEADACHE (slight headache) in an 83-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concomitant products included ATORVASTATIN, LISINOPRIL, HYDROCHLOROTHIAZIDE, ACETYLSALICYLIC ACID (ASPIRINE) and CALCIUM for an unknown indication.   On 18-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 11-Apr-2021, the patient experienced OFF LABEL USE (second dose early) and HEADACHE (slight headache). The patient was treated with NAPROXEN SODIUM (ALEVE) on 11-Apr-2021 for Headache, at a dose of 1 dosage form. On 11-Apr-2021, OFF LABEL USE (second dose early) and HEADACHE (slight headache) had resolved.            Action taken with mRNA-1273 in response to the events was not applicable.
On 3/2/00, the pt experienced bruising. She subsequently developed idiopathic thrombocytopenic purpura and on 3/4/00 was hospitalized to get blood work done. She was treated with IV TB to increase her platelet count. On 3/6/00, the pt was discharged, but was to return to the hospital to get more blood work done.
No adverse event; Since after June 1 multiple temperature excursions; 6 doses administered since June 1 after multiple temperature excursions; This spontaneous case was reported by an other health care professional and describes the occurrence of PRODUCT TEMPERATURE EXCURSION ISSUE (Since after June 1 multiple temperature excursions), POOR QUALITY PRODUCT ADMINISTERED (6 doses administered since June 1 after multiple temperature excursions) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AS7173B) for COVID-19 prophylaxis.     No Medical History information was reported.    In June 2023, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. In June 2023, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Since after June 1 multiple temperature excursions) and POOR QUALITY PRODUCT ADMINISTERED (6 doses administered since June 1 after multiple temperature excursions). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, PRODUCT TEMPERATURE EXCURSION ISSUE (Since after June 1 multiple temperature excursions), POOR QUALITY PRODUCT ADMINISTERED (6 doses administered since June 1 after multiple temperature excursions) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for PRODUCT TEMPERATURE EXCURSION ISSUE (Since after June 1 multiple temperature excursions) and POOR QUALITY PRODUCT ADMINISTERED (6 doses administered since June 1 after multiple temperature excursions).    No concomitant medication was reported.  No treatment information was reported.
had to get a flu shot,never been sicker; Initial information regarding an unsolicited valid non-serious case received from a consumer (patient) via company through social media on 22-Nov-2020.  This case involves a patient of unknown demographic who experienced when had to get a flu shot,never been sicker (illness) ,while the patient was treated with INFLUENZA VACCINE.  The patient's medical history, past medical treatment(s), concomitant therapy, past vaccination(s) and family history were not provided.  On an unknown date, the patient received suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) at an unknown dose via unknown route at an unknown administration site for prophylactic vaccination.  On an unknown ate (latency unknown) after the initiation of the suspect drug when patient reported that twice in the last 20 years when patient had to get a flu shot,never been sicker (illness)   Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of the reporting , event outcome was unknown .  There will be no information available on batch number for this case .
6 inch oblong rash at injection site (sub q back of left arm), hard to touch and tender.
Shoulder pain that still has not resolved. Doing physical therapy and it improves but still hurt when he lifts weights.
Site: Redness at Injection Site-Medium, Systemic: Numbness (specify: facial area, extremities)-Medium, Systemic: Tingling (specify: facial area, extemities)-Medium, Additional Details: Arm pain going down to palm of hand developed 2 days after shot, accompanied by numbness and tingling of fingers
Narrative:  Patient received two doses of covid vaccine. Admitted approx. one month later for chest pain. Found to have NSTEMI, decompensated and required medical intervention (epi and CPR). PEA arrest shortly after and family made DNR/DNI so no CPR was attempted.
Pain at injection site for two days, chills and fever of 99 same night of shot with sweating all night. Feeling weak and dizzy. No treatment.
getting covid from the first covid vaccine; getting covid from the first covid vaccine.; This is a spontaneous report from a non-contactable consumer (patient's sister) reported that a female patient of an unspecified age received the first dose of bnt162b2 (PFIZER-BIONTECH COVID-19 MRNA VACCINE), via an unspecified route of administration on an unspecified date as SINGLE DOSE for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The consumer wanted to know if her sister should receive the second dose of the COVID vaccine due to her having side effects and getting COVID from the first COVID vaccine on an unspecified date. The outcome of the event was unknown.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
Information has been received from a lawyer regarding a case in litigation concerning a female patient of unknown age. No information was received regarding the patient's past medical history, concurrent conditions, or concomitant medication. On an unknown date in 2013, the patient was inoculated with the ZOSTAVAX (lot number, dosage and route of administration not provided) at a pharmacy, as recommended for routine adult health maintenance and for the prevention of shingles. The ZOSTAVAX did not prevent shingles as intended, and the patient subsequently contracted a persistent strain of herpes zoster. On an unknown date in 2016, the patient was treated by a physician for a vesicular outbreak, which was diagnosed as herpes zoster or shingles. The outcome of the events is unknown. As a direct and proximate result of the ZOSTAVAX vaccine, and/or despite receiving ZOSTAVAX for long-term prevention of shingles, the patient suffered painful injuries and damages, and required extensive medical care and treatment. As a further proximate result, the patient has suffered and will continue to suffer significant medical expenses, and pain and suffering, and other damages. Additional information has been requested.
Information has been received from a medical assistant referring to an unspecified number of patients of unknown age and gender. There was no medical history or drug reaction/allergies reported. On unknown dates the patients were vaccinated with improperly stored doses of VARIVAX (Merck) (lot # L019126 with expired date 27-MAY-2017, K007784 with expired date 28-MAY-2016, K005182 with expired date 10-APR-2016; dose and route were unknown). No concomitant therapy was reported. No adverse effects were reported. This is one of two reports received from the same reporter (1512USA006790). Additional information has been requested.
Redness, red bumps, itching. Hydrocortisone cream. No change in symptoms.
Patient states that her arm was incredibly sore when she woke up the morning after vaccination and that she couldn't lift it. She saw her prescriber later in the week her had her take an oral NSAID to help with pain and inflammation. Provider told her she would refer her to physical therapy if the pain in her arm did not resolve.
loss of taste; weakness; soreness; fever; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 01-Mar-2021 and was forwarded to Moderna on 01-Mar-2021.    This spontaneous case was reported by a consumer and describes the occurrence of AGEUSIA (loss of taste), ASTHENIA (weakness), PAIN (soreness) and PYREXIA (fever) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Feb-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced AGEUSIA (loss of taste), ASTHENIA (weakness), PAIN (soreness) and PYREXIA (fever). At the time of the report, AGEUSIA (loss of taste), ASTHENIA (weakness), PAIN (soreness) and PYREXIA (fever) outcome was unknown.            Reporter did not allow further contact
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient.  A 66-year-old male patient received BNT162b2 (BNT162B2), on 09Mar2021 at 15:00 as dose 1, single (Lot number: EN6205), in right arm, on 30Mar2021 at 14:00 as dose 2, single (Lot number: ER8732), in right arm and on 12Oct2021 at 11:00 as dose 3 (booster), single (Lot number: FF2590) at the age of 65 years, in right arm for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: positive. Therapeutic measures were taken as a result of vaccination failure, covid-19.
Pt stated 2-3 days after immunization started to develop tongue burning, throat felt raw, trouble breathing, body aches and nausea. Symptoms were progressing. Pt notified pharmacy on 10/24/16.
Initial muscle soreness hours post injection 3 days later soreness much milder but vaccine site firm raised swollen red and warm to touch (about the size of an egg) Pain under the axila  same arm as injection (lymph nodes) Sore throat, productive cough and congestion began 1 week after injection. Currently 11 days post injection and site is still red swollen warm and firm. Lymph nodes still inflamed in the axila on same arm as injection. Still having congestion and cough.
Left deltoid pain- chronic since the day after immunization to reporting date with no change in pain severity. Difficulty with left shoulder ROM > 90 degrees in any direction.
On 04/15/2021 at 6:15pm, experienced severe joint pain, sharp headache, and felt pain/pressure in throat area - it was difficult to swallow. No fever. Symptoms not present next morning but returned around 4:30pm on 04/16/2021 and continued on a nightly basis for over a week. On 04/30/2021 joint pain disruptive to sleep, work, regular activities, and also developed extreme night sweats, fatigue, severe anxiety, tremors, unintentional weight loss, and throat pain was increasing. Saw Dr. on 04/30/2021 and labs were ordered. Anxiety continued to increase, getting a deep breath almost impossible, and I could not work so went back to Dr.
Lethargic, Tiredness, muscle aches all over, Blood sugar numbers increased significantly
Almost immediately developed irritability/fussiness, which lasted for 6 days. On day 2 following injection her right thigh became swollen, red, and firm. Local reaction peaked on day 3, then subsided gradually-gone by day 6. For entire week following immunization, sleep was very disturbed-child waking frequently (every 30 min to 1 hour)- fussy/irritable. Symptoms resolved by day 6
pt states that lt deltoid arm started to get sore 2 hrs p/inject, had a small bump, but went away especially upon waking up in AM & periods of inactivity arm becomes stiff
Left side paralysis would come and go. Would lose all sensation and therefore would fall and was unable to walk. At this time, my left side is still losing feeling. Also had two menstrual cycles in under 30 days
3cm x 4.5cm erythematous irregularly shaped area on the left lateral humerus and a smaller circular area noted proximally, both areas firm; no fluctuance or warmth.
Caller states all of them, have a low temperature of 97.2; Vomiting; diarrhea heavily; it was bile and tasted like medicine, very bile tasting; she was feeling strange/she had that awful; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 95 year-old female patient received bnt162b2 (BNT162B2), administered in arm left, administration date 13Mar2021 (Lot number: EN6073) at the age of 95 years as dose 1, single for covid-19 immunisation. Relevant medical history included: "Glaucoma" (unspecified if ongoing), notes: drops in both eyes twice a day; "gone down from 140 lbs to 90 lbs" (unspecified if ongoing), notes: it was all before and she had some other problems; "height has gone down from 5 feet 4 inches to about 5 feet 2 inches" (unspecified if ongoing); "she does have a small esophagus" (unspecified if ongoing); "one of the lungs has a little problem breathing" (unspecified if ongoing); "one of the lungs has a little problem breathing" (unspecified if ongoing), notes: breathe into the lungs and she does it for 5-6 minutes twice a day.; "she has nothing but bones with skin stretched over" (unspecified if ongoing); "she has nothing but bones with skin stretched over" (unspecified if ongoing), notes: pinch the skin and he put the covid in that; "She lost so much of her fat and muscle" (unspecified if ongoing); "She lost so much of her fat and muscle" (unspecified if ongoing). The patient took concomitant medications. The following information was reported: FEELING ABNORMAL (non-serious) with onset 15Mar2021, outcome "unknown", described as "she was feeling strange/she had that awful"; VOMITING (non-serious) with onset 16Mar2021, outcome "recovered" (16Mar2021), described as "Vomiting"; DIARRHOEA (non-serious) with onset 16Mar2021, outcome "recovered" (16Mar2021), described as "diarrhea heavily"; TASTE DISORDER (non-serious) with onset 16Mar2021, outcome "recovered", described as "it was bile and tasted like medicine, very bile tasting"; BODY TEMPERATURE DECREASED (non-serious), outcome "unknown", described as "Caller states all of them, have a low temperature of 97.2". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of vomiting, diarrhoea.   Additional information: The concomitant medication included drops for eyes for glaucoma in both eyes twice a day.  No follow-up attempts are possible. No further information is expected.
Immunizations given 8-11-08.  On 8-12-08 patient reports he had fever 100.8, body aches, headache and chills.  Symptoms lasting 1 wk with gradual improvement daily.
Pain and extreme swelling in (R) arm. Redness pain with mobility to ER 10/13/12 received IM ROCEPHIN and script for PO CLEOCIN. Started vomiting and took only a couple of antibiotics. Later put on BACTRIM.
next day, thigh became very red and swollen.  two days after, redness spread, swelling became worse and painful. Child would not walk on leg due to pain and would not touch the area.
Received shot/flu within 5 minutes felt blanked out, happened twice - felt dizzy -> lied on floor -> tachycardia -> extremities cold -> near syncope extreme called 911 -> had rigors -> went to ER.
At 3:30 pm HPV 9 1 dose given, pt fainted right away, skin color pale, clammy and cold. Responded after 10 sec. Vital signs stable.